ProCE Banner Activity

First-line Osimertinib for EGFR-Mutated Advanced NSCLC: Barriers to Access and Future Directions

Clinical Thought
In this expert commentary, gain insights into barriers to osimertinib access worldwide along with future directions in the management of patients with advanced EGFR-mutant NSCLC.

Released: July 29, 2021

Expiration: July 28, 2022

Share

Faculty

David Planchard

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

David Planchard, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Celgene, Novartis, Merck, Pfizer, Roche, and Samsung.